Orgasm men are capable of achieving them is supported by men who have reported having multiple, consecutive orgasms, particularly without ejaculation. Males who experience dry orgasms can often produce multiple orgasms, as the refractory period is reduced. An increased infusion of the hormone oxytocin during ejaculation is believed to be chiefly responsible for the refractory period, and the amount by which oxytocin is increased may affect the length of each refractory period. Another chemical which is considered to be responsible for the male refractory period is prolactin, which represses dopamine, which is responsible for sexual arousal. Because of this, there is
Cabazitaxel mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Cabazitaxel Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival